388
Participants
Start Date
March 1, 2003
Primary Completion Date
December 1, 2003
Study Completion Date
December 16, 2003
Hib-MenCY-TT vaccine
Three doses during the primary vaccination and one booster dose administered intramuscularly (IM) in left thigh.
Hib-MenC-TT vaccine
Three doses during the primary vaccination and one booster dose administered intramuscularly (IM) in left thigh.
Menjugate ®
Three doses during the primary vaccination and one booster dose administered intramuscularly (IM) in left thigh.
Infanrix penta ®
Three doses during the primary vaccination and one booster dose administered intramuscularly (IM) in right thigh.
Infanrix hexa ®
Three doses during the primary vaccination and one booster dose administered intramuscularly (IM) in right thigh.
GSK Investigational Site, Asse
GSK Investigational Site, Ghent
GSK Investigational Site, Drongen
GSK Investigational Site, Sint-Amandsberg
GSK Investigational Site, Oudenaarde
GSK Investigational Site, Merelbeke
GSK Investigational Site, Maldegem
GSK Investigational Site, Berlin
GSK Investigational Site, Berlin
GSK Investigational Site, Berlin
GSK Investigational Site, Berlin
GSK Investigational Site, Hamburg
GSK Investigational Site, Flensburg
GSK Investigational Site, Flensburg
GSK Investigational Site, Bredstedt
GSK Investigational Site, Kirchlengern
GSK Investigational Site, Löhne
GSK Investigational Site, Detmold
GSK Investigational Site, Niedernhausen
GSK Investigational Site, Munich
GSK Investigational Site, Munich
GSK Investigational Site, Olching
GSK Investigational Site, Nördlingen
GSK Investigational Site, Kaufering
GSK Investigational Site, Cham
GSK Investigational Site, Leipzig
Lead Sponsor
GlaxoSmithKline
INDUSTRY